Kiromic Biopharma, Inc. - FORM S-1 - EX-10.20 - May 11, 2020

Attached files

file filename
EX-23.2 - EX-23.2 - Kiromic Biopharma, Inc.d853469dex232.htm
EX-14.1 - EX-14.1 - Kiromic Biopharma, Inc.d853469dex141.htm
EX-10.28 - EX-10.28 - Kiromic Biopharma, Inc.d853469dex1028.htm
EX-10.25 - EX-10.25 - Kiromic Biopharma, Inc.d853469dex1025.htm
EX-10.24 - EX-10.24 - Kiromic Biopharma, Inc.d853469dex1024.htm
EX-10.23 - EX-10.23 - Kiromic Biopharma, Inc.d853469dex1023.htm
EX-10.22 - EX-10.22 - Kiromic Biopharma, Inc.d853469dex1022.htm
EX-10.21 - EX-10.21 - Kiromic Biopharma, Inc.d853469dex1021.htm
EX-10.19 - EX-10.19 - Kiromic Biopharma, Inc.d853469dex1019.htm
EX-10.18 - EX-10.18 - Kiromic Biopharma, Inc.d853469dex1018.htm
EX-10.17 - EX-10.17 - Kiromic Biopharma, Inc.d853469dex1017.htm
EX-10.16 - EX-10.16 - Kiromic Biopharma, Inc.d853469dex1016.htm
EX-10.15 - EX-10.15 - Kiromic Biopharma, Inc.d853469dex1015.htm
EX-10.14 - EX-10.14 - Kiromic Biopharma, Inc.d853469dex1014.htm
EX-10.13 - EX-10.13 - Kiromic Biopharma, Inc.d853469dex1013.htm
EX-10.12 - EX-10.12 - Kiromic Biopharma, Inc.d853469dex1012.htm
EX-10.11 - EX-10.11 - Kiromic Biopharma, Inc.d853469dex1011.htm
EX-10.10 - EX-10.10 - Kiromic Biopharma, Inc.d853469dex1010.htm
EX-10.9 - EX-10.9 - Kiromic Biopharma, Inc.d853469dex109.htm
EX-10.8 - EX-10.8 - Kiromic Biopharma, Inc.d853469dex108.htm
EX-10.7 - EX-10.7 - Kiromic Biopharma, Inc.d853469dex107.htm
EX-10.6 - EX-10.6 - Kiromic Biopharma, Inc.d853469dex106.htm
EX-10.5 - EX-10.5 - Kiromic Biopharma, Inc.d853469dex105.htm
EX-10.4 - EX-10.4 - Kiromic Biopharma, Inc.d853469dex104.htm
EX-10.3 - EX-10.3 - Kiromic Biopharma, Inc.d853469dex103.htm
EX-10.2 - EX-10.2 - Kiromic Biopharma, Inc.d853469dex102.htm
EX-10.1 - EX-10.1 - Kiromic Biopharma, Inc.d853469dex101.htm
EX-4.1 - EX-4.1 - Kiromic Biopharma, Inc.d853469dex41.htm
EX-3.2 - EX-3.2 - Kiromic Biopharma, Inc.d853469dex32.htm
EX-3.1 - EX-3.1 - Kiromic Biopharma, Inc.d853469dex31.htm
S-1 - S-1 - Kiromic Biopharma, Inc.d853469ds1.htm

Exhibit 10.20

 

LOGO   

Corporate Address

Fannin South Professional

Building, Suite 140

7707 Fannin Street

Houston, Texas 77054

t: 832.968.4888

ADDENDUM TO EMPLOYMENT AGREEMENT

 

EMPLOYEE: Maurizio Chiriva-Internati    EFFECTIVE DATE: January 1, 2020

Annual cash compensation increase to: $380,000 annually

 

/s/ Maurizio Chiriva-Internati
Maurizio Chiriva-Internati, CEO and President

/s/ Tony Tontat

Tony Tontat, CFO and COO

 

844.KEY.CURE | www.kiromic.com

Kiromic Biopharma, Inc. Reports